Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $167,133 | $131,314 | $196,245 | $241,544 |
| % Growth | 27.3% | -33.1% | -18.8% | – |
| Cost of Goods Sold | $11,074 | $35,049 | $52,827 | $62,176 |
| Gross Profit | $156,059 | $96,265 | $143,418 | $179,368 |
| % Margin | 93.4% | 73.3% | 73.1% | 74.3% |
| R&D Expenses | $21,425 | $24,537 | $36,082 | $32,105 |
| G&A Expenses | $78,654 | $52,790 | $70,062 | $46,790 |
| SG&A Expenses | $78,654 | $52,790 | $70,062 | $46,790 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $78,586 | $6,996 | $34,237 | -$3,378 |
| Operating Expenses | $178,665 | $84,323 | $140,381 | $75,517 |
| Operating Income | -$22,606 | $11,942 | $3,037 | $103,851 |
| % Margin | -13.5% | 9.1% | 1.5% | 43% |
| Other Income/Exp. Net | $25,124 | $51,718 | $32,974 | -$31,646 |
| Pre-Tax Income | $2,518 | $63,660 | $36,011 | $72,205 |
| Tax Expense | $6,550 | $9,841 | $41,230 | -$4,148 |
| Net Income | -$4,032 | $52,154 | -$33,361 | $57,138 |
| % Margin | -2.4% | 39.7% | -17% | 23.7% |
| EPS | -0.22 | 3.02 | -1.98 | 3.46 |
| % Growth | -107.3% | 252.5% | -157.2% | – |
| EPS Diluted | -0.22 | 2.94 | -1.98 | 3.34 |
| Weighted Avg Shares Out | 18,290 | 17,298 | 16,868 | 16,630 |
| Weighted Avg Shares Out Dil | 18,290 | 17,757 | 16,868 | 17,246 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,055 | $7,711 | $2,046 | $886 |
| Interest Expense | $3,037 | $656 | $1,799 | $19,619 |
| Depreciation & Amortization | $35,239 | $36,521 | $43,394 | $50,946 |
| EBITDA | $40,794 | $100,837 | $81,204 | $142,770 |
| % Margin | 24.4% | 76.8% | 41.4% | 59.1% |